Second cancers following in situ carcinoma of the breast
โ Scribed by Silvia Franceschi; Fabio Levi; Carlo La Vecchia; Lalao Randimbison; Van-Cong Te
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- French
- Weight
- 69 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Carcinoma in situ (CIS) of the breast has increased manyfold in incidence rates and as a proportion of new breast cancers following the introduction of mammographic breast screening. To provide population-based estimates of invasive breast cancer risk following CIS, we linked data on 249 incident primary CIS (median age 53 years) to the Cancer Registry of the Swiss Canton of Vaud (about 600,000 inhabitants) over the period 1977-1994. Women with concurrent invasive cancers of the breast were not included. Standardized incidence ratios (SIR) were determined according to the exact Poisson distribution, with stratification for age and year of diagnosis. A total of 24 cases of breast cancer vs. 3.4 expected [SIR โซุโฌ 7.2, 95% confidence interval (CI): 4.6-10.6], and 7 cases of other neoplasms (except non-melanomatous skin cancer) vs. 6.9 expected (SIR โซุโฌ 1.0, 95% CI: 0.4-2.1) were observed. The SIR was 10.4 during the first year, 5.6 between 1 and 4 years, and 7.7 after H5 years after CIS diagnosis. SIRs were consistent in women below and above age 55 years, but somewhat higher for ductal (SIR โซุโฌ 8.6) than lobular (SIR โซุโฌ 4.2) CIS. Six deaths from breast cancer were observed vs. 1.5 expected (standardized mortality ratio โซุโฌ 4.0, 95% CI: 1.5-8.7). In 13/19 ductal CIS, but in 2/4 lobular CIS, invasive cancer occurred in the same breast. In most women, CIS and subsequent invasive cancer showed the same morphological (i.e., ductal or lobular) features. The cumulative risk of breast cancer was 16% 10 years after CIS diagnosis, emphasizing the importance of adequate surveillance of women after CIS of the breast.
๐ SIMILAR VOLUMES
Background: Second primary neoplasms (SPN) have been seen with diseases such as breast cancer and Hodgkin's disease. Therapeutic agents used for their treatment have been found responsible for the development of SPN in some cases. In addition, genetic factors are known to contribute to their develop
Background. Ductal carcinoma in situ (DCIS) of the male breast is an uncommon disease, accounting for approximately 7% of all male breast carcinomas. Compared with invasive carcinomas of the breast, the prognosis associated with DCIS in men is excellent; however, clinical features, pathology, and tr
From 1963-1972, women treated with radical mastectomy for early cancer of the breast were randomly assigned to treatment with thiotepa weekly for one year (N = 90) or no further therapy (N = 77). Fifteen patients subsequently developed second cancers, six in the thiotepa-treated group, and nine in t
Ductal carcinoma in situ (DCIS) was a relatively uncommon disease process when we relied on palpation to detect breast lesions. With the advent of more widespread mammography screenings, the surgeon is faced with a welcome opportunity to prevent cancer by dealing with a precursor lesion. Discovering